Sobi’s sNDA is supported by data from the AVA ... Avatrombopag, known under the brand name DOPTELET, is a thrombopoietin receptor agonist (TPO-RA) that does not compete with thrombopoietin ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibrosis and severe ...

Swedish Orphan Biovitrum AB (publ) (Sobi), an international specialty health-care company, aims to be recognized as a global leader in providing access to innovative treatments that transform the ...

Sobi's acquired immunology drugs (Astra's Synagis ... New products like long-acting hemophilia drug Altuviiio and Altuvoct (branded names in US and Europe, respectively), myelofibrosis drug ...